Biogen is ready to roll on lecanemab production, CFO says
Biogen begins cutting jobs following disastrous debut of its Alzheimer's drug - The Boston Globe
More Layoffs Hit Biogen as Drugmaker Cuts Multiple Sclerosis Team – NBC Boston
Biogen gives up releasing Alzheimer's drug Aduhelm in Korea < Pharma < Article - KBR
Drug companies are making an accounting change after the SEC cracked down on Biogen - MarketWatch
Biogen's ALS Drug Tofersen Gets Partial Backing From FDA Panel - Bloomberg
Biogen Wins US Approval for Drug to Treat Rare Form of ALS - BNN Bloomberg
Biogen - Биоген - Photos | Facebook
Biogen Seeks to Sublease Cambridge, Weston Properties - Banker & Tradesman
Biogen's Qalsody Is a First for ALS Treatments - Bloomberg
Biogen gears up Swiss manufacturing facility for potential aducanumab rollout | Fierce Pharma
Biogen Uses its Own Superspreader Event to Aid COVID-19 Research | The Scientist Magazine®
Stocks making the biggest moves midday: Apple, Netflix, Biogen, Canopy Growth and more
Biogen (BIIB) Loses Bid to Revive Patent on Tecfidera MS Drug - Bloomberg
Biogen - Wikipedia
Biogen teams up with Ginkgo Bioworks in gene therapy manufacturing pact - MedCity News
Biogen shakes up R&D role, splitting it into two
Biogen Earnings Beat Expectations. All Eyes Are on the Alzheimer's Drug. | Barron's
Biogen's new Alzheimer's drug slows cognitive decline: study - Boston Business Journal
Biogen Announces Positive Phase 1 Results, Plan to License and Develop Ionis Pharmaceuticals' Investigational Therapy BIIB067 for Familial ALS - Muscular Dystrophy Association
Biogen: Strong Prospects With A Low Valuation (NASDAQ:BIIB) | Seeking Alpha
